What medications may increase the risk for hepatitis B (HBV) (Hep B) reactivation?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

Medications that may increase the risk for hepatitis B reactivation include:

  • Anti-CD20 antibodies: Ofatumumab (Arzerra), rituximab (Rituxan)

  • Antineoplastic agents (including methotrexate) [108, 109]

  • Glucocorticoids, especially with abrupt discontinuation [110, 111]

  • Interleukin receptor antagonists: Ustekinumab (Stelara), [112] anakinra (Kineret), tocilizumab (Actemra)

  • Nucleoside and nucleotide therapy, due to immune reconstitution syndrome or discontinuation of antiviral therapy with anti-HBV properties

  • T-cell regulator: Abatacept (Orencia) [113]

  • Tumor necrosis factor (TNF) inhibitors: Infliximab (Remicade), [112] etanercept (Enbrel), [112] adalimumab (Humira), [112] certolizumab pegol (Cimzia), golimumab (Simponi, Simponi Aria)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!